Roivant Sciences Ltd. (ROIV)
NEUTRALFundamental
34
Precio
$36.47
Capitalización Bursátil
$26.29B
Parte 1 · Cuánto vale la empresa
Resumen
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance y Liquidez
Ingresos
$8M
Últimos 12 meses (hasta 30/6/2026)
Beneficio Neto
$-266M
Últimos 12 meses (hasta 30/6/2026)
Flujo de Caja Libre
$-759M
Patrimonio Neto Total
$4.53B
Pasivo Total
$416M
Ratio de Liquidez
16.72
Cobertura de Intereses
-
Deuda/EBITDA
-
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$41.82
Precio Actual
$36.47
Margen de Seguridad
+12.8%
Rango de Valor Justo
$39.73 - $43.91
Métodos de Estimación
Métricas de Valoración
Ratio P/E
-
ROE
-6.6%
Ratio P/B
6.21
P/FCF
-
Margen Bruto
-
ROIC
-9.4%
Radar de Rentabilidad
Value Creation (Economic Moat)
ROIC
-9.4%
WACC
10.5%
ROIC − WACC
-19.9 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Criterios de Análisis Fundamental
Superado (7)
- EPS shows upward trend
- Price CAGR 23.63%
- Debt/Equity ratio
- Current Ratio
- Low reliance on intangibles
- Analyst Consensus 89% Buy
- Share Dilution -22.5%
Fallido (11)
- ROIC -9.4%
- P/B Ratio 6.21
- Operating Margin -7914.8%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -6.1%
- Revenue Growth 5Y -19.1%
- Earnings Surprise avg -2.3%
- Net Margin Trend -3535.0% vs -2111.8%
- Piotroski F-Score 1/9
No disponible (9)
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Preocupaciones financieras graves
Calidad de los Beneficios
Baja calidad: investigue la contabilidad
Dilución de Acciones
Recomprando acciones. Favorable para el accionista
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Mr. Matthew Gline | CEO & Director | 41 |
| Dr. Eric Venker M.D., Pharm.D. | President & CEO of Immunovant | 38 |
| Dr. Mayukh Sukhatme M.D. | President, Chief Investment Officer & Director | 49 |
| Dr. Frank M. Torti M.B.A., M.D. | President & Vant Chair | 46 |
| Mr. Richard Pulik | Chief Financial Officer | 45 |
| Ms. Jennifer Humes | Chief Accounting Officer | 44 |
| Mr. Ian Rosenblum | Chief Information Officer | - |
| Mr. Sam Kaplan | General Counsel | - |
| Ms. Kelly Graff | Head of People | - |
| Mr. Alex Gasner | Executive Vice President of Roivant Health | - |
Riesgo de Auditoría
5
Riesgo del Consejo
7
Riesgo de Compensación
10
Riesgo de Derechos del Accionista
4
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Latest News
Recent headlines for ROIV, sourced from Markets Gazette.
- 19d agoPOSITIVERoivant Expects FDA to Approve First Major Drug
Roivant Sciences Ltd. is anticipating FDA approval for its novel drug targeting a severe skin condition, with a market launch projected for September. CEO Matt Gline expressed optimism about the drug's potential. This development represents a significant milestone for Roivant, potentially unlocking a new revenue stream and validating its research and development pipeline. Investors will be closely watching the official FDA decision, as approval could lead to substantial growth and market share gains in the dermatology sector.
via Markets Gazette